Last reviewed · How we verify
Ceftriaxone treatment
At a glance
| Generic name | Ceftriaxone treatment |
|---|---|
| Sponsor | Hackensack Meridian Health |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Ceftriaxone Pulse Dose for Post-Treatment Lyme Disease (EARLY_PHASE1)
- Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial (NA)
- Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP (PHASE4)
- Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae (PHASE2)
- Treatment Responses of Early Syphilis to Ceftriaxone Plus Doxycycline (PHASE4)
- Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Streptococcus (PHASE3)
- A Platform Trial for Gram Negative Bloodstream Infections (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ceftriaxone treatment CI brief — competitive landscape report
- Ceftriaxone treatment updates RSS · CI watch RSS
- Hackensack Meridian Health portfolio CI